sb 220025 has been researched along with Innate Inflammatory Response in 1 studies
SB 220025: inhibits p38 mitogen-activated protein kinase; structure in first source
SB220025 : Am member of the class of imidazoles carrying piperidin-4-yl, 4-fluophenyl and 2-aminopyrimidin-4-yl substituents at posiitons 1, 4 and 5 respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jackson, JR | 1 |
| Bolognese, B | 1 |
| Hillegass, L | 1 |
| Kassis, S | 1 |
| Adams, J | 1 |
| Griswold, DE | 1 |
| Winkler, JD | 1 |
1 other study available for sb 220025 and Innate Inflammatory Response
| Article | Year |
|---|---|
Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models.
Topics: Animals; Anti-Inflammatory Agents; Calcium-Calmodulin-Dependent Protein Kinases; Chronic Disease; Di | 1998 |